PEPTIDE-BASED INHIBITORS OF PTP1B / NCK1 INTERACTION AND METHODS OF MAKING AND USING SAME

Sergio Dall'Angelo; Meghan Hamer; Emily Martin

PEPTIDE-BASED INHIBITORS OF PTP1B / NCK1 INTERACTION AND METHODS OF MAKING AND USING SAME

Sergio Dall'Angelo (Inventor)
, Meghan Hamer (Inventor)
, Emily Martin (Inventor)

Research output: Patent

Abstract

(EN) The disclosure relates generally to synthetic peptides which bind NCK1. The invention further relates to methods of using the peptides for inhibiting an interaction between NCK1 and PTP1B, and for treating a disease or disorder associated with insulin resistance, including type 2 diabetes and obesity.
(FR) La divulgation concerne d'une manière générale des peptides synthétiques qui se lient à NCK1. L'invention concerne en outre des procédés d'utilisation des peptides pour inhiber une interaction entre NCK1 et PTP1B, et pour traiter une maladie ou un trouble associé à la résistance à l'insuline, comprenant le diabète de type 2 et l'obésité.

Original language	English
Patent number	WO/2026/050386
IPC	C07K 7/06 2006.1,A61K 38/00 2006.1,A61K 38/08 2019.1,A61K 38/16 2006.1,A61P 3/04 2006.1,A61P 3/10 2006.1
Priority date	23/06/25
Filing date	27/08/25
Publication status	Published - 5 Mar 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2026050386Licence: CC0

Cite this

@misc{7ee61d23cdd545b8a98cef0b00eb550d,

title = "PEPTIDE-BASED INHIBITORS OF PTP1B / NCK1 INTERACTION AND METHODS OF MAKING AND USING SAME",

abstract = "(EN) The disclosure relates generally to synthetic peptides which bind NCK1. The invention further relates to methods of using the peptides for inhibiting an interaction between NCK1 and PTP1B, and for treating a disease or disorder associated with insulin resistance, including type 2 diabetes and obesity. (FR) La divulgation concerne d'une mani{\`e}re g{\'e}n{\'e}rale des peptides synth{\'e}tiques qui se lient {\`a} NCK1. L'invention concerne en outre des proc{\'e}d{\'e}s d'utilisation des peptides pour inhiber une interaction entre NCK1 et PTP1B, et pour traiter une maladie ou un trouble associ{\'e} {\`a} la r{\'e}sistance {\`a} l'insuline, comprenant le diab{\`e}te de type 2 et l'ob{\'e}sit{\'e}.",

author = "Sergio Dall'Angelo and Meghan Hamer and Emily Martin",

year = "2026",

month = mar,

day = "5",

language = "English",

publisher = "World Intellectual Property Organization",

type = "Patent",

note = "WO/2026/050386; C07K 7/06 2006.1,A61K 38/00 2006.1,A61K 38/08 2019.1,A61K 38/16 2006.1,A61P 3/04 2006.1,A61P 3/10 2006.1",

}

TY - PAT

T1 - PEPTIDE-BASED INHIBITORS OF PTP1B / NCK1 INTERACTION AND METHODS OF MAKING AND USING SAME

AU - Dall'Angelo, Sergio

AU - Hamer, Meghan

AU - Martin, Emily

PY - 2026/3/5

Y1 - 2026/3/5

N2 - (EN) The disclosure relates generally to synthetic peptides which bind NCK1. The invention further relates to methods of using the peptides for inhibiting an interaction between NCK1 and PTP1B, and for treating a disease or disorder associated with insulin resistance, including type 2 diabetes and obesity. (FR) La divulgation concerne d'une manière générale des peptides synthétiques qui se lient à NCK1. L'invention concerne en outre des procédés d'utilisation des peptides pour inhiber une interaction entre NCK1 et PTP1B, et pour traiter une maladie ou un trouble associé à la résistance à l'insuline, comprenant le diabète de type 2 et l'obésité.

AB - (EN) The disclosure relates generally to synthetic peptides which bind NCK1. The invention further relates to methods of using the peptides for inhibiting an interaction between NCK1 and PTP1B, and for treating a disease or disorder associated with insulin resistance, including type 2 diabetes and obesity. (FR) La divulgation concerne d'une manière générale des peptides synthétiques qui se lient à NCK1. L'invention concerne en outre des procédés d'utilisation des peptides pour inhiber une interaction entre NCK1 et PTP1B, et pour traiter une maladie ou un trouble associé à la résistance à l'insuline, comprenant le diabète de type 2 et l'obésité.

M3 - Patent

M1 - WO/2026/050386

Y2 - 2025/08/27

PB - World Intellectual Property Organization

ER -

PEPTIDE-BASED INHIBITORS OF PTP1B / NCK1 INTERACTION AND METHODS OF MAKING AND USING SAME

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this